China SXT Pharmaceuticals (SXTC) Invested Capital (2018 - 2025)

China SXT Pharmaceuticals' Invested Capital history runs 8 years deep, the most recent figure standing at $4475.0 for Q3 2025.

• In Q3 2025, Invested Capital fell 50.72% year-over-year to $4475.0; the TTM figure through Sep 2025 stood at $1.2 million (down 63.03% YoY), while the FY2025 annual figure was $15.4 million, up 7.11% from the prior year.
• Invested Capital was $4475.0 for Q3 2025 at China SXT Pharmaceuticals, down from $15.4 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $28.1 million in Q1 2021 to a low of $4475.0 in Q3 2025.
• Historically, Invested Capital has averaged $9.3 million across 5 years, with a median of $8.3 million in 2021.
• The sharpest annual moves came in 2021 and 2023: Invested Capital surged 4527.81% in 2021, then slumped 98.36% in 2023.
• A 5-year view of Invested Capital shows it stood at $2.1 million in 2021, then sank by 43.04% to $1.2 million in 2022, then plunged by 98.36% to $19737.0 in 2023, then sank by 54.0% to $9080.0 in 2024, then plunged by 50.72% to $4475.0 in 2025.
• The last three Invested Capital figures came in at $4475.0 (Q3 2025), $15.4 million (Q1 2025), and $9080.0 (Q3 2024), per Business Quant data.